Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 11

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 11
---
of Linea DNA, each of which will have different permitted uses.

| Quality                
 Grade                  |    |                                        | Permitted                                                        
 Use                                                              | Company                                   
 Status                                    |
| GLP                    |    |                                        | Research                                                         
 and pre-clinical discovery                                       | Currently                                 
 available                                 |
| GMP                    
 for Starting Materials |    |                                        | DNA                                                              
 critical starting materials for the production of mRNA therapies | Planned                                   
 availability in January 2025              
 (GMP Site 1)                              |
| GMP                    |    |                                        | DNA                                                              
 biologic, drug substance and/or drug product                     | Planned                                   
 availability in first half of CY 2026 (1) 
 (GMP Site 2)                              |
|                        | -1 | Dependent                              
 on the availability of future funding. |                                                                  |                                           |

We are currently manufacturing LineaDNA pursuant
to Good Laboratory Practices (“GLP”) and have recently completed the buildout of a fit for purpose manufacturing facility
within our current Stony Brook, NY laboratory space capable of producing LineaDNA IVT templates under Good Manufacturing Practices (“GMP”)
suitable for use as a critical starting material for clinical and commercial mRNA therapeutics. We are currently conducting final certification
of the facility and anticipate full operational status by the end of January 2025 (“GMP Site 1”). Accordingly, on January
10, 2025 the Company announced its readiness to accept GMP customer orders for IVT templates to be manufactured in GMP Site 1 upon full
operation status. We also plan to offer additional capacity for LineaDNA IVT templates as well as capacity for LineaDNA materials manufactured
under GMP suitable for use as, or incorporation into, a biologic, drug substance and/or drug product, with availability expected during
the first half of calendar year 2026, dependent upon the availability of future funding and customer demand (“GMP Site 2”).
GMP is a quality standard used globally and by the U.S. Food and Drug Administration (“FDA”) to ensure pharmaceutical quality.
Drug substances are the pharmaceutically active components of drug products.

Segment Business Strategy

Our business strategy for our Therapeutic
DNA Production Services is to capitalize upon the rapid growth of mRNA therapies in the near term via our planned near term future availability
of LineaDNA IVT templates manufactured under GMP at our GMP Site 1, while at the same time laying the basis for additional clinical and